137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-2436 ◽

2010 ◽

Vol 16 (7) ◽

pp. 2187-2197 ◽

Cited By ~ 10

Author(s):

Marlies H.G. Langenberg ◽

Petronella O. Witteveen ◽

Jeanine M. Roodhart ◽

Henk M.W. Verheul ◽

Marja Mergui-Roelvink ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3045 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3045-3045

Author(s):

M. H. Langenberg ◽

P. Witteveen ◽

J. M. Roodhart ◽

M. P. Lolkema ◽

H. Verheul ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Cited By ~ 42

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

Cancer Science ◽

10.1111/cas.12014 ◽

2012 ◽

Vol 103 (12) ◽

pp. 2135-2138 ◽

Cited By ~ 11

Author(s):

Isamu Okamoto ◽

Tokuzo Arao ◽

Masaki Miyazaki ◽

Taroh Satoh ◽

Kunio Okamoto ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Peptide Vaccine ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Clinical Phase ◽

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Retrospective Study ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Tyrosine Kinase Inhibitor ◽

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research ◽

10.1158/0008-5472.can-07-5809 ◽

2008 ◽

Vol 68 (12) ◽

pp. 4754-4762 ◽

Cited By ~ 86

Author(s):

Caroline A. Heckman ◽

Tanja Holopainen ◽

Maria Wirzenius ◽

Salla Keskitalo ◽

Michael Jeltsch ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

NMR in Biomedicine ◽

10.1002/nbm.961 ◽

2005 ◽

Vol 18 (5) ◽

pp. 308-321 ◽

Cited By ~ 44

Author(s):

Markus Rudin ◽

Paul M. J. McSheehy ◽

Peter R. Allegrini ◽

Martin Rausch ◽

Diana Baumann ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Contrast Agent ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3069-8 ◽

2016 ◽

Vol 78 (2) ◽

pp. 259-269 ◽

Cited By ~ 20

Author(s):

Junning Cao ◽

Jian Zhang ◽

Wei Peng ◽

Zhiyu Chen ◽

Songhua Fan ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinases ◽

Phase I Study ◽

Growth Factor Receptor ◽

Selective Inhibitor ◽

Chinese Patients ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal Of Pathology ◽

10.2353/ajpath.2008.071074 ◽

2008 ◽

Vol 173 (1) ◽

pp. 265-277 ◽

Cited By ~ 59

Author(s):

Cornelia Halin ◽

Hermann Fahrngruber ◽

Josef G. Meingassner ◽

Guido Bold ◽

Amanda Littlewood-Evans ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Skin Inflammation ◽

Vascular Endothelial ◽